Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

EU IMI StemBANCC Consortium

The University of Oxford is the academic lead institution for StemBANCC ( This 5-year research programme funded by the EU Innovative Medicines Initiative (IMI) involving academic and industry partners across 11 countries with the objective of developing human induced pluripotent stem cells as a platform for drug discovery. 

Richard Wade-Martins leads Work Package 8 (WP8: Central Nervous System: Neurodegenerative and Neurodysfunctional Diseases), with the aim of providing disease-relevant, human in vitro systems in neurons and glia derived from iPSC generated from well-characterised patients with neurodegenerative and neurodysfunctional disorders.

The StemBANCC consortium is an academic-industry partnership that will provide well characterized human induced pluripotent stem cell (iPSC) lines in an accessible and sustainable bio-bank across a range of diseases. StemBANCC will support collection of skin biopsies from Parkinson's patients in the OPDC cohort.